C-kit-negative gastrointestinal stromal tumors (GISTs) are uncommon, and there have been few reports about the diagnosis and treatment of c-kit-negative GISTs in the stomach. We report the case of a patient who was diagnosed with a huge and atypical GIST in the stomach. The GIST was completely resected and finally diagnosed as c-kit-negative GIST based on immunohistochemical staining of tumor cells, which were negative for CD117 and CD34 and positive for Discovered on GIST-1 (DOG1). C-kit-negative GISTs could be treated by complete resection and/or imatinib, which is the same treatment for c-kit-positive GISTs.
Introduction
Gastrointestinal stromal tumor (GIST) is one of the most common sarcomatous tumors detected in gastrointestinal tract. 1 The incidence of GIST is 7 to 10 cases per million people in Europe and the USA.
2,3 However, in Korea, the incidence is higher than that in Europe or the USA, a 16 to 22 cases per million people. 4 GISTs are derived from interstitial cells of Cajal, and they have three histological types, spindled, epithelioid, and mixedtype cells. 5 Identifying the expression of CD117, also known as kit, by immunohistochemical (IHC) staining is necessary to diagnose GISTs. CD117 expression can be found in over 95% of GISTs. 6 However, CD117 expression is not found in the 5% of c-kit-negative GISTs. Although, in those cases, additional staining with Discovered on GIST-1 (DOG1, also known as ANO1)
can be helpful to confirm a GIST, 7 the diagnosis and treatment of c-kit negative GISTs remain obscure.
Here, we have encountered a c-kit-negative GIST case, and we are going to report on the diagnosis and treatment of that tumor. ) and CD34 (Fig. 4B) . However, DOG1 was observed in the membrane and cytoplasm of the tumor cells (Fig. 4C ). There was no involvement of the resected margins. Consequently, this tumor was diagnosed as a c-kit negative GIST with a high risk of malignant behavior. Post-operative recovery was uneventful, and the patient was discharged on post-operative day 7.
Case Report

Discussion
The stomach is the most common organ (50% to 60%) in which GISTs are found. The other organs are the small intestine (30% to 35%), colon (5%), and esophagus (＜1%). Less than 5%
of GISTs are found in the omentum, mesentery, and retroperitoneum, and those tumors are called extra-GISTs (E-GISTs). EGISTs occur in relatively high proportions in Korea (10%). 8 In fact, the identification KIT or PDGFRA mutation by gene analysis is needed to make a confirmatory diagnosis. In general, the identification of CD117 expression by IHC staining is enough to diagnosis GISTs, clinically. Moreover, CD117 or CD34 expression is found in more than 90% of GISTs. 8 However, they are not expressed in some GISTs. In CD117-or CD34-negative cases, DOG1 expression could be identified if the patients are clinically suspected of having GISTs. DOG1 expression is detected in many c-kit-negative GISTs, 8 and one previous study reported that more than 90% of c-kit-negative GISTs were positive for DOG1. 9 Several studies have reported that DOG1 is more sensitive than CD117 and more helpful, especially in ckit-negative GISTs. [10] [11] [12] Thus, for patients who are clinically suspected of having c-kit negative GISTs, DOG1 expression should be checked.
C-kit-positive GISTs are treated with surgery and/or imatinib. Imatinib is prescribed for patients with GISTs based on For unresectable GISTs, neoadjuvant or palliative imatinib and/ or surgery is recommended. 14 For c-kit-positive GISTs, 400 mg daily imatinib can be used for neoadjuvant, adjuvant, and palliative treatment. 15, 16 Despite these treatment modalities, the 5-year survival rate of c-kit-positive GISTs is known roughly to be 48% to 65%, and the tumors usually recur. The prognosis of GISTs depends on tumor size, the number of mitoses, chemotherapy, and complete resection. 17 On the other hand, the prognoses and predictive factors for prognosis of c-kit-negative GISTs remain unclear.
However, complete resection and adjuvant imatinib, if possible, should be considered for c-kit-negative GISTs also because of the possibility of KIT or PDGFRA mutation, as in c-kitpositive GISTs. 18 Imatinib is a competitive inhibitor of tyrosine kinases, such as KIT and PDGFRA, 19 and several studies have
shown that the c-kit-negative GISTs still have mutated KIT or PDGFRA despite the absence of IHC expression. 18 Therefore, surgery and imatinib should be used as a therapeutic strategy for c-kit-negative GISTs. In addition, some studies reported the effectiveness of imatinib. 7 However, c-kit-negative GISTs commonly have PDGFRA D842 mutations, and in such cases, imatinib resistance develops. 9 Thus, clinicians should consider this mutation when considering imatinib treatment for c-kitnegative GISTs.
We reported on our patient with a c-kit-negative GIST.
The tumor, which was located in the stomach, was completely 
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